10-K: Bone Biologics Faces Going Concern Amidst Clinical Trials

Bone Biologics Corporation reports recurring operating losses and substantial doubt about its ability to continue as a going concern, despite progress in its spinal fusion clinical study and recent capital raises.

Summary

• Bone Biologics Corporation is a clinical-stage medical device company focused on bone regeneration in spinal fusion using its proprietary NELL-1 protein in combination with demineralized bone matrix (DBM).
• The company's lead product candidate, NB1 (NELL-1/DBM), is classified as a device/drug combination product requiring FDA Pre-Market Approval (PMA) for commercialization in the United States.
• A multicenter, prospective, randomized pilot clinical study for NB1 in adult subjects undergoing transforaminal lumbar interbody fusion (TLIF) for degenerative disc disease (DDD) commenced in Australia in 2024, with up to 30 subjects.
• The primary endpoints for the Australian pilot study are fusion success at 12 months and change from baseline in the Oswestry Disability Index pain score.
• The company incurred a net loss of $3.1 million in 2025, a decrease from $4.1 million in 2024, and has accumulated losses of approximately $88.1 million since inception.
• Research and development expenses decreased by 50.23% to $1,060,191 in 2025 from $2,130,385 in 2024, primarily due to lower protein needs during the pilot clinical study.
• General and administrative expenses increased by 4.12% to $2,174,751 in 2025 from $2,088,776 in 2024, mainly due to compensation for an independent director appointed in late 2024.
• Cash used in operating activities was $2.7 million in 2025, down from $4.1 million in 2024.
• The company's cash balance as of December 31, 2025, was $5.3 million, and it expects this to fund operations into the fourth quarter of 2026.
• Management and the independent auditor have expressed substantial doubt about the company's ability to continue as a going concern.
• A 1-for-6 reverse stock split was effected on June 10, 2025.
• The company completed a public offering in June 2025, raising net proceeds of $4,352,792 from the sale of common stock, pre-funded warrants, and Series D and E warrants.
• An At The Market (ATM) offering program generated net proceeds of $347,549 in 2025 from the sale of 52,843 shares of common stock.
• The company holds exclusive worldwide licenses from UCLA TDG for NELL-1, with 5 issued patents expiring between 2026 and 2033, and a new patent application filed in 2025.
• Milestone payments are due to UCLA TDG upon clinical and regulatory achievements, including $250,000 for pivotal study enrollment, $500,000 for PMA, and $1,000,000 for first commercial sale.
• The company has two full-time employees and relies heavily on third-party contractors for regulatory approval, clinical management, manufacturing, marketing, and sales.
• Operating expenditures for the next twelve months are estimated at $4.9 million.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to the explicit 'going concern' warning from both management and auditors, coupled with significant accumulated losses and the early stage of product development, despite some clinical progress and recent capital raises.

Positives

• Successfully initiated a first-in-man pilot clinical study for NB1 in Australia in 2024, a critical step towards commercialization.
• The pilot clinical study design was reviewed and agreed upon by the FDA's Division of Orthopedic Devices, supporting progression to a pivotal clinical trial in the U.S.
• NELL-1 technology has been validated in sheep and non-human primate models, demonstrating effective bone formation without inflammation.
• The company has an exclusive worldwide license for the NELL-1 technology platform from UCLA TDG, providing a strong intellectual property foundation.
• Successfully completed a public offering in June 2025, raising $4.35 million in net proceeds, and utilized an ATM facility for additional capital, improving its cash position to $5.3 million by year-end 2025.
• Research and development expenses decreased by over 50% in 2025 compared to 2024, indicating more efficient use of resources during the pilot study phase.
• The company's intellectual property portfolio includes 5 issued U.S. patents and a new patent application, covering NELL-1 manufacture, compositions, and use in various clinical applications.

Negatives

• The company has a limited operating history and has incurred accumulated losses of approximately $88.1 million since inception to December 31, 2025.
• Recurring operating losses and current cash position raise substantial doubt about the company's ability to continue as a going concern, as noted by both management and the independent auditor.
• The company is in an early stage of development, and its products are not expected to be commercially available for five or more years, with no assurance of successful development or commercialization.
• Significant additional capital will be needed to achieve FDA approval for a spine interbody fusion indication, including costs related to a pivotal clinical trial.
• The company relies heavily on third parties for raw material supply, manufacturing, preclinical and clinical trials, and other services, which may not always be available on a timely basis or at affordable costs.
• The lead product candidate, NB1, is regulated as a Class III medical device, requiring a costly and time-consuming Pre-Market Approval (PMA) process from the FDA.
• The company has only two full-time employees, which could pose challenges for managing future growth and complex operations.

Risks

• The company has a limited operating history and recurring operating losses, raising substantial doubt about its ability to continue as a going concern.
• Significant additional capital will be required to fund operations, including pivotal clinical trials and FDA approval, and there is no assurance that such financing will be available on satisfactory terms or at all.
• Product candidates are at an early stage of development and may not be successfully developed or commercialized, with no guarantee of favorable results in later clinical trials or regulatory approval.
• FDA regulation is costly and time-consuming, potentially delaying or preventing commercialization, and approval policies or regulations may change.
• Any product candidate advanced into clinical trials may cause unacceptable adverse events, leading to delays, halts, or denial of regulatory approval.
• Delays in the commencement or completion of clinical testing could increase costs and delay or prevent the ability to complete product development or generate revenues.
• Difficulty in enrolling subjects in clinical trials could delay or prevent the start and completion of trials.
• Operating in foreign countries (e.g., Australia for pilot study) exposes the company to differing regulatory requirements, economic weakness, political instability, and foreign currency fluctuations.
• Inability to obtain regulatory approval in non-U.S. jurisdictions would prevent product marketing abroad.
• Even if regulatory approval is received, the product may face future development and regulatory difficulties, including ongoing post-approval requirements and potential withdrawal of approval.
• The results of preclinical studies and early clinical trials are not necessarily predictive of future results, and later trials may not demonstrate adequate effectiveness and safety.
• The company's ability to compete may be limited or eliminated if it cannot protect its intellectual property, and patents may be challenged, invalidated, or circumvented.
• Substantial costs may be incurred from litigation or other proceedings relating to patent and other intellectual property rights, including potential infringement claims by third parties.
• The terms of existing patents may not be sufficient to effectively protect product candidates and business, with current patents expiring between 2026 and 2033.
• Failure to comply with obligations under license agreements, such as with UCLA TDG, could result in loss of important rights.
• Commercial success depends on attaining significant market acceptance among physicians, patients, and healthcare payors, which is not guaranteed even if approved.
• Product candidates, if approved, may not be covered or adequately reimbursed by third-party payors, impacting demand and pricing.
• Healthcare legislative measures aimed at reducing costs may negatively impact the business and results of operations.
• The company operates in a highly competitive environment with larger, more resourced competitors.
• Future success depends on the performance and continued service of key officers and directors, and the loss of these individuals could harm the business.
• Public health crises could materially and adversely affect business and results of operations, including delays in clinical trials and supply chain disruptions.
• Significant disruptions of information technology systems, computer system failures, or breaches of information security could adversely affect the business.
• Product liability lawsuits could cause substantial liabilities and limit commercialization.
• The ability to use net operating losses (NOLs) to offset future taxable income may be subject to limitations under Section 382 of the Internal Revenue Code.
• Non-compliance with healthcare laws and regulations could lead to criminal sanctions, civil penalties, and reputational harm.
• The price of common stock may fluctuate substantially due to various factors, including Nasdaq listing requirements, financing efforts, and market conditions.
• Future sales and issuances of common stock or equity-linked securities could result in additional dilution for stockholders and cause share price to fall.
• Failure to comply with Nasdaq continued listing standards could result in delisting.
• The company does not intend to pay cash dividends, limiting returns to share price appreciation.
• Preemptive rights held by the CEO and CFO to participate in future financings could impair the ability to raise capital.
• If shares become subject to penny stock rules, it would become more difficult to trade them.
• Inability to establish appropriate internal financial reporting controls and procedures could lead to reporting failures or restatements.
• Risk of securities class action litigation due to stock price volatility.

Future Outlook

The company anticipates completing its first-in-man pilot clinical trial in Australia 12 months after enrolling the 30th patient. The data from this pilot study will be used to enable a future, larger U.S. pivotal clinical study, which is a prerequisite for submitting a Pre-Market Approval (PMA) application to the FDA. Significant ongoing investment in NELL-1 development is expected as the company prepares for its pivotal clinical study. The company will continue to attempt to raise additional debt and/or equity financing to fund future operations and provide additional working capital, as its current cash is expected to fund operations only into the fourth quarter of 2026.

Management Comments

• Management believes NELL-1 will address unmet clinical challenges for effective bone regeneration, especially in hard healers, by providing target specific control over bone regeneration.
• Management believes that NELL-1 technology will perform as well as other growth factors in non-union trauma cases, addressing an $8 billion global market opportunity.
• Management believes NELL-1's novel characteristics, target-specific mechanism of action, efficacy, safety, and affordability position the product for application in various procedures beyond lumbar spinal fusion, including osteoporosis.
• Management does not expect the product to see the same adverse events with NELL-1/DBM as have been observed with other commercially available proteins in cervical spine fusion.
• Management believes its scientific evidence validates the many benefits of NELL-1, citing a comprehensive database of over 80 research publications and abstracts.
• Management states that continued capital funding is critical to facilitate the development of Nell-1 technology through the clinical regulatory path.

Industry Context

StockSavvy.ai notes that Bone Biologics operates in the highly competitive orthobiologics and medical device industry, characterized by rapidly advancing technologies and a strong emphasis on intellectual property. The company faces substantial competition from large, established players like Medtronic, Stryker, Globus Medical, and DePuy-Synthes, which possess significantly greater resources. The focus on spinal fusion, a large segment of the orthopedic market, positions Bone Biologics against these formidable competitors. The company's strategy to address challenges related to rapid, uncontrolled bone growth and inflammatory responses with its NELL-1/DBM combination product aims to fill a clinical gap, particularly in light of past FDA warnings regarding other recombinant human proteins in cervical spine fusion. However, its early clinical stage and limited resources present a significant challenge in this capital-intensive and highly regulated sector.

Comparison to Industry Standards

• The company's lead product, NB1, aims to provide target-specific control over bone regeneration, addressing issues like rapid, uncontrolled bone growth, less dense bone formation, unwanted bone formation, cysts, swelling, and intense inflammatory response, which are challenges associated with current bone regeneration compounds.
• NB1 is positioned as an alternative to autograft, which is currently the optimal procedure for spinal fusion but is limited by complications such as pain, increased surgical time, and infection.
• The company explicitly compares NELL-1's proinflammatory response to rhBMP-2, stating that NELL-1 induced normal healing while rhBMP-2 induced significant swelling and intense inflammatory response in a rat femoral onlay model, suggesting a potential safety advantage over a commercially available protein that was the subject of an FDA Public Health Notification.
• Management believes NELL-1 technology will perform as well as other growth factors in non-union trauma cases, a global market opportunity estimated at $8 billion by Fortune Business Insights.
• The company targets the global osteoporosis market, an $11.2 billion opportunity per Evercore analyst reports, by proposing systemic use of NELL-1 to stimulate bone regeneration and increase bone density, aiming to counter a major medical challenge.

Corporate Governance

Legal Proceedings

• The company is not presently a party to any legal proceedings that, if determined adversely, would individually or in aggregate have a material adverse effect on its business, results of operations, financial condition, or cash flows.

Related Party Transactions

• No director, officer, proposed nominee, or 5% beneficial owner, or their relatives/spouses, has had any direct or indirect material interest in any transaction to which the company was a party since January 1, 2024, or in any proposed transaction.

Stakeholder Impact

• Shareholders face significant risk due to the company's 'going concern' warning, accumulated losses, and the early stage of product development, which could lead to further dilution from future capital raises or a decline in share price.
• Employees (currently two full-time) and consultants are critical to the company's operations, and the ability to attract and retain qualified personnel is essential for achieving development objectives.
• Customers (spine surgeons and patients) are the ultimate beneficiaries of the company's product, but commercialization is years away and dependent on successful clinical trials and regulatory approval.
• Creditors and investors in debt financing face risks associated with the company's substantial debt and its ability to generate sufficient cash flow to service that debt, given its current financial position.
• UCLA TDG, as the licensor of the core technology, is impacted by the company's progress through milestone payments and future royalties, but also faces the risk of license termination or reduction if diligence milestones are not met.

Next Steps

• Complete the first-in-man pilot clinical study in Australia, anticipated 12 months after enrolling the 30th patient.
• Use pilot clinical trial data from the Australia study to enable a future, larger U.S. pivotal clinical study.
• Prepare for submission of a Pre-Market Approval (PMA) application to the FDA following successful pivotal clinical trials.
• Continue to raise additional equity or debt capital to fund future operations and product development programs.
• Ongoing significant investment in NELL-1 development as the company prepares for its pivotal clinical study.
• The 2026 Annual Meeting of Stockholders is scheduled for August 11, 2026, with stockholder proposals and director nominations due by May 13, 2026.

Key Dates

Recommendation

A seasoned investor or institution would likely issue a 'strong sell' recommendation. The explicit 'going concern' warning from both management and the independent auditor, coupled with substantial accumulated losses ($88.1 million) and a cash runway only into Q4 2026, indicates severe financial distress. While the company has made some clinical progress and raised capital, the product is still in early-stage human trials, requiring significant future funding and facing a long, uncertain regulatory path. The high-risk profile, intense competition, and fundamental financial instability outweigh any positive clinical developments at this stage, making the investment highly speculative with substantial downside risk.

Keywords

Bone Regeneration, Spinal Fusion, NELL-1, DBM, Medical Device, Clinical Stage, FDA Approval, PMA, Orthobiologics, Degenerative Disc Disease, Biotechnology, Warrants, Capital Raise, Going Concern, Intellectual Property, Nasdaq, SEC Filing, 10-K